What PULMOTREE does

Pulmotree Medical GmbH is a Munich-based life-science startup specializing in respiratory drug deposition and integrated inhalation therapies. The company's core product is the Kolibri Mesh Nebulizer, a vibrating mesh nebulizer platform featuring guided inhalation with haptic feedback, an Intelligent Administration System (INAS) for breath-triggered aerosol generation, and a Key & Lock mechanism that restricts the device to approved drugs. Complementary products include the Flamingo Spirometer (CE-marked and FDA-approved mobile lung function monitor measuring FEV1, FVC, and PEF), the Connect App, and the Connect Eco-System — a networked platform that links nebulizers, inhalers, and monitoring devices with patients, physicians, and clinical study centers for adherence monitoring, inhalation quality feedback, and remote therapy optimization. Pulmotree also develops APEX, a proprietary model for predicting pulmonary drug deposition from real-time breathing profiles.\n\nPulmotree operates as a B2B technology partner to pharmaceutical and biotech companies developing inhaled biologics and nebulized therapies, providing the Kolibri as the device component of drug-device combination products under a one-stop-shop model spanning concept through production. Revenue is generated through licensing of the Kolibri platform (upfront fees, development milestones, per-unit royalties), co-development service fees with pharma partners, hardware sales of Kolibri and Flamingo devices (including supply to CROs for clinical trials), and consulting services for respiratory drug delivery. GTM is anchored in scientific credibility — the CEO is an ISAM Board Member and conference chairman — and driven by enterprise field sales, conference presence (ISAM, RDD, DDL, ERS, PDD, ATS), and scientific publications.

Name

PULMOTREE

Legal name

Pulmotree Medical GmbH

Website

https://pulmotree.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Pulmotree is a Munich-based life-science startup that develops the Kolibri Mesh Nebulizer and connected respiratory therapy ecosystem for pharmaceutical partners, CROs, physicians, and patients needing precise inhaled drug delivery and adherence monitoring.

Ownership category

akta.pro rank

Headquarters

HQ city

Munich

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Licensing of Kolibri Mesh Nebulizer Platform: Licensing the Kolibri mesh nebulizer technology to pharmaceutical partners for drug-device combination products. The platform is customized for specific medications, patient groups, and market strategies. Revenue is generated through upfront licensing fees, development milestones, and per-unit royalties.
2. Co-development Partnerships with Pharma: Joint development of combination products with pharmaceutical companies. Partners receive full development support from concept to production under a one-stop-shop model. Revenue includes development fees, regulatory milestone payments, and commercial royalties.
3. Device Sales (Kolibri, Flamingo Spirometer): Sale of proprietary medical devices — Kolibri mesh nebulizer and Flamingo spirometer — through pharmaceutical partnerships and potentially direct channels. Devices are also used in clinical trial settings with CROs.
4. Consulting Services: Medical and consulting services for respiratory drug delivery, spanning from product conception to production. Includes expertise in aerosol therapy, regulatory affairs, and clinical development support.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels11 records

Core offering

PULMOTREE develops and licenses a vibrating mesh nebulizer platform (Kolibri) with guided inhalation technology, haptic feedback, and a connected therapy ecosystem for targeted pulmonary drug delivery. The company works with pharmaceutical and biotech partners on drug-device combination products from concept through production, and also sells the Flamingo spirometer and Connect App as complementary devices within its Connect Eco-System. Revenue is generated via platform licensing with milestone and royalty payments, co-development fees, device sales, and consulting services.

Product overview

PULMOTREE offers a platform-plus-modules product portfolio centered on the Connect Eco-System, a fully networked therapy platform for respiratory diseases. The core product is the Kolibri Mesh-Nebulizer, a vibrating mesh nebulizer with guided inhalation technology, haptic feedback, and the Intelligent Administration System (INAS) for breath-triggered aerosol delivery. Complementary modules include the Flamingo Spirometer (CE/FDA-cleared mobile lung function monitor) and the Connect App (smartphone interface for therapy control, adherence monitoring, and inhalation quality feedback). Products are designed for Plug & Play interoperability within the ecosystem, supporting both PULMOTREE's own devices and partner devices, with data transmitted to physicians and clinical study centers.

Differentiator

Problem solved

Functional benefit

Brands

• Kolibri Mesh-Nebulizer: Vibrating mesh nebulizer with guided inhalation technology, haptic feedback, and intelligent administration system for optimal lung deposition
• Connect Eco-System
• Flamingo Spirometer
• Connect App

Products and services

• Kolibri Mesh-Nebulizer Vibrating mesh nebulizer platform with guided inhalation technology, haptic feedback, and Intelligent Administration System (INAS) for breath-triggered aerosol generation; customized for pharmaceutical partners as the device component of drug-device combination products and supplied to CROs for clinical trials.
• Flamingo Spirometer Mobile, app-based spirometer for measuring FEV1, FVC, and PEF with validated accuracy per ISO 26782, ISO 23747, and ATS/ERS 2005 standards; CE-marked and FDA-approved; used by patients at home and clinicians for lung function monitoring and integrated into the Connect Eco-System.
• Connect App Smartphone application providing therapy planning and reminders, digital inhalation feedback for optimal drug deposition, centralized device control, personal therapy diary, and long-term therapy and lung function monitoring; enables remote physician support and partner-system integration.
• Connect Eco-System Networked therapy platform that connects Pulmotree's nebulizers, inhalers, and monitoring devices with patients and physicians, providing automatic therapy data storage, encrypted data exchange, adherence monitoring, inhalation quality assessment, centralized therapy control, and remote patient monitoring; supports Plug & Play integration of partner devices for CROs and clinical study sites.

Quantifiable outcome

• Higher deposition in target lung regions demonstrated for OCK4 (a heparin derivative) compared to spontaneous unguided breathing, as shown in a collaborative case study with Aptar Pharma using Kolibri guided breathing profile.
• +3 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature9 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• Aptar PharmacoreTechnology or IntegrationAptar Pharma collaborated with Pulmotree to develop the Kolibri Mesh Nebuliser featuring guided inhalation technology with haptic feedback for biologic delivery. A collaborative case study demonstrated the Kolibri guided breathing profile achieved higher deposition in target regions for OCK4 (a heparin derivative) compared to spontaneous unguided breathing. Jonathan Mulpas from Aptar is listed as a partnering contact.
• KEYENCEminorOthersKEYENCE supplied Pulmotree with a digital microscope for lab expansion, enhancing R&D capabilities. The microscope enables more precise tailoring of mesh structures, deeper understanding of aerosol generators, and more targeted drug delivery solutions.
• German Center for Lung Research (DZL)coreStrategic or Co-development PartnerCollaborated with Pulmotree researchers on the RDD2026 poster 'Predicting Pulmonary Drug Deposition Using Real-Time Connected Inhalation Data.' DZL researchers Otmar Schmid contributed expertise in deposition modeling alongside Pulmotree's connected device data.
• Helmholtz MunichcoreStrategic or Co-development PartnerCollaborated with Pulmotree on pulmonary drug deposition prediction research presented at RDD2026. Otmar Schmid from Helmholtz Munich co-authored the research on integrating real-time inhalation data with in silico deposition modeling.
• RWTH Aachen University (TANDEM Program)minorStrategic or Co-development PartnerCEO Ulf Krueger serves as PhD student mentor for the TANDEM program at RWTH Aachen University, supporting doctoral research in aerosol medicine and inhalation technology.
• International Society for Aerosols in Medicine (ISAM)coreOthersPulmotree CEO Ulf Krueger is a Board Member of ISAM and serves as chairman of the networking group 'New Devices, Emerging Therapies and e-Health.' The company actively participates in ISAM Congress events and the society's podcast.
• PDD Workshop Sponsors (including Miccados, Harro Höfliger, Aerogen, Amcor, GS Bio-Inhalation, MEGGLE, H&T Presspart, Resyca, Copley Scientific, IMA Group, Intertek, Insmed, PureIMS, Catalent, DFE Pharma)minorGTM or Marketing PartnerPulmotree sponsored the 11th PDD Workshop alongside multiple industry companies including Miccados, Harro Höfliger, Aerogen, Amcor, GS Bio-Inhalation, MEGGLE, H&T Presspart, Resyca, Copley Scientific, IMA Group, Intertek, Insmed, PureIMS, Catalent, and DFE Pharma, demonstrating active engagement in the respiratory drug delivery community.
• PAConsult GmbHminorImplementation/ SI/ Consulting PartnerPartnered with Pulmotree Consulting to deliver a 4-hour German-language webinar on 'medical device and combination product labeling.' Paul Malinovski and Beate Seidel served as trainers alongside Pulmotree.
• PARIminorStrategic or Co-development PartnerCEO Ulf Krueger held various positions in the research and development department at PARI before founding Pulmotree. PARI is a leading company in inhalation therapy systems.
• VecturaminorStrategic or Co-development PartnerCEO Ulf Krueger previously served as Director of Fox Nebuliser Programs at Vectura, responsible for the entire mesh nebulizer business. This prior experience informed Pulmotree's technology development.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• PARI: Established manufacturer of nebulizer systems for respiratory drug delivery. Pulmotree's CEO previously held R&D roles at PARI, and PARI competes in the same vibrating-mesh / breath-enhanced nebulizer category that Kolibri targets.
• Aerogen: Specialist in vibrating-mesh aerosol drug-delivery technology used in acute and critical-care nebulization. Aerogen is a direct technological peer to Kolibri, competing for inhaled-drug combination-product partnerships with the same pharma customers.
• Vectura (Philip Morris): Inhalation drug-delivery developer where Pulmotree's CEO was previously Director of Fox Nebuliser Programs. Vectura develops nebulizer and DPI platforms for pharma combination products and is a direct comparator in mesh-nebulizer business strategy.

Broad incumbents

• Aptar Pharma: Global drug-delivery device and component supplier that is Pulmotree's disclosed co-development partner for Kolibri. Aptar competes in adjacent device categories (DPIs, spray pumps, elastomeric components) and serves the same pharma combination-product market.
• OMRON Healthcare: Large medical-device company with a respiratory portfolio including nebulizers and connected respiratory monitoring. OMRON is a broader incumbent rather than a direct mesh-nebulizer peer but competes for similar patient and clinical customers.
• Catalent: Large CDMO with significant inhalation and drug-device combination-product capabilities. Catalent is a broader incumbent competing for the same pharma combination-product co-development deals, including as a co-sponsor at PDD alongside Pulmotree.

Emerging players

• PureIMS: Specialist in inhalation drug-device combination products with a focus on dry-powder and unit-dose systems. PureIMS is a comparable emerging combination-product developer targeting the same pharma partner pipeline.
• Insmed (inhaled antibiotic franchise): Biopharma company that has commercialized ARIKAYCE delivered via a mesh-nebulizer pathway (PARI/eFlow). Insmed represents an example customer archetype for Pulmotree - inhaled therapies whose delivery device is mission-critical.

Others

• Copley Scientific: Supplier of testing equipment and reference instruments for inhaled drug-delivery development (cascade impactors, flow meters). Sits in Pulmotree's ecosystem as a tools vendor used across the same pharma development workflows.
• Sensirion: Sensor manufacturer whose flow and pressure sensors are commonly integrated into connected nebulizers and spirometers. Sensirion supplies enabling technology for the kind of inhalation-quality and breathing-profile data capture that Kolibri and Flamingo rely on.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/Pulmotree-107485353922628
• LinkedInde.linkedin.com/company/pulmotree-medical
• Instagraminstagram.com/pulmotree

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PULMOTREE